Hillstream Biopharma (NASDAQ:CNTN) Downgraded by Wall Street Zen to Sell

Hillstream Biopharma (NASDAQ:CNTN) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

Separately, Weiss Ratings initiated coverage on Hillstream Biopharma in a research report on Monday, March 9th. They set a “sell (e+)” rating on the stock. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of “Sell”.

Hillstream Biopharma Price Performance

NASDAQ CNTN opened at $3.26 on Friday. Hillstream Biopharma has a 12-month low of $0.95 and a 12-month high of $9.08. The stock has a market cap of $184.70 million, a price-to-earnings ratio of -0.82 and a beta of 1.57.

Hillstream Biopharma (NASDAQ:CNTN) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $0.54 earnings per share (EPS) for the quarter.

About Hillstream Biopharma

Hillstream BioPharma, Inc, a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company’s product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar; IC50 against PI3K-delta and HDAC6, which is also known to downregulate; c-myc, a cancer drug target; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells.